End-to-end characterization of AAV manufacturing process using charge detection mass spectrometry
Molecular Therapy Methods & Clinical Development · 2025-12 · 33 (4) · 101607
DOI: 10.1016/j.omtm.2025.101607 ↗Kurz gefasst
Fachartikel in der Zeitschrift Molecular Therapy Methods & Clinical Development, 2025-12. Verfasst von Lohra M Young und 4 weiteren Autor:innen. Beteiligte Einrichtung: Megadalton Solutions, Inc., Bloomington, IN 47404, USA. Die Arbeit wurde bisher 4-mal zitiert (Crossref) und nennt 34 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0).
Abstract (Originalsprache)
Kein Abstract verfügbar.
Schlagwörter
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Megadalton Solutions, Inc., Bloomington, IN 47404, USA.
- ThermoFisher Scientific, Viral Vector Services, Plainville, MA 02762, USA.
Zitieren
APA
Young, L. M., Draper, B. E., Jarrold, M. F., Froelich, C. A., & Motevalian, S. P. (2025). End-to-end characterization of AAV manufacturing process using charge detection mass spectrometry. Molecular Therapy Methods & Clinical Development. https://doi.org/10.1016/j.omtm.2025.101607
Vancouver
Young LM, Draper BE, Jarrold MF, Froelich CA, Motevalian SP. End-to-end characterization of AAV manufacturing process using charge detection mass spectrometry. Molecular Therapy Methods & Clinical Development. 2025. doi:10.1016/j.omtm.2025.101607
BibTeX
@article{Young2025,
author = {Young, Lohra M and Draper, Benjamin E and Jarrold, Martin F and Froelich, Clifford A and Motevalian, Seyed Pouria},
title = {End-to-end characterization of AAV manufacturing process using charge detection mass spectrometry},
journal = {Molecular Therapy Methods & Clinical Development},
year = {2025},
doi = {10.1016/j.omtm.2025.101607}
}
EUVIMED